Kairos Pharma, LTD. KAPA
Kairos Pharma, LTD. (NYSE: KAPA) is an oncology drug developer. Its lead program, ENV 105 (carotuximab), is in Phase 2 for Androgen-therapy-resistant castrate-resistant prostate cancer (with apalutamide). Its next catalyst on record is ENV-105 (carotuximab): Kairos Pharma targets completion of the modified Phase 2 trial of ENV-105 in or before the fourth quarter of 2027. (Q4 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ENV-105 (carotuximab) — Kairos Pharma targets completion of the modified Phase 2 trial of ENV-105 in or before the fourth quarter of 2027. (Q4 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ENV 105 | Castrate-resistant prostate cancer, randomized Phase 2 with apalutamide | antibody | Phase 2 |
| ENV 105 | EGFR-resistant non-small cell lung cancer, Phase 1 with osimertinib | antibody | Phase 1 |
| KROS 201 | Recurrent glioblastoma (activated T cell therapy) | cell therapy | Phase 1 |
| KROS 101 | Solid tumors (GITR ligand small molecule) | small molecule | Pre-clinical |
| KROS 102 | Autoimmune diseases (GITR antagonist) | small molecule | Pre-clinical |
| KROS 301 | RelA-positive solid tumors | small molecule | Pre-clinical |
| KROS 401 | Triple negative breast cancer / tumor microenvironment | protein/peptide | Pre-clinical |
| ENV 205 | Chemotherapy-resistant prostate cancer / cachexia | antibody | Pre-clinical |
Recent results and decisions
- Oct 6, 2026positive Interim Phase 2 analysis: median PFS 17.7 months with ENV-105 plus apalutamide vs 2 months with apalutamide alone, P=0.0008.
Median PFS was 17.7 months with the combination compared with 2 months with apalutamide alone (P=0.0008).
Filing - Oct 6, 2026met ENV-105 plus apalutamide demonstrated statistically significant improvement in progression-free survival versus apalutamide alone in interim Phase 2 analysis.
Median PFS was 17.7 months with the combination compared with 2 months with apalutamide alone (P=0.0008).
Filing - Jul 22, 2026n/a Strategic collaboration with Bayer to evaluate ENV-105 in combination with XOFIGO (radium-223) in bone-involving mCRPC.
Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.